Skip to content

Phagos Secures €25M for AI-Enhanced Phage Therapies Against Antibiotic-Resistant Bacteria

Phagos' innovative approach to bacterial diseases could revolutionize animal health. With €25 million in funding, the company is set to scale its solutions and combat antimicrobial resistance.

in this picture there are bowls, mugs and spoons in the kitchen sink. Beside to it there are...
in this picture there are bowls, mugs and spoons in the kitchen sink. Beside to it there are bottle, sanitizers, tissues and bowls.

Phagos Secures €25M for AI-Enhanced Phage Therapies Against Antibiotic-Resistant Bacteria

Paris-based Phagos, a biotech startup, has secured €25 million in Series A funding. The company specialises in AI-enhanced bacteriophage (phage) therapies to combat bacterial diseases, focusing initially on animal health.

Phagos combines microbiology and artificial intelligence to create precise, personalized phage treatments. The company has filed a patent for its AI technology that predicts phage and bacterial interactions. This innovation allows Phagos to tailor treatments to specific bacterial strains, tackling antibiotic resistance effectively.

Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos has already received authorization to market personalized phage-based veterinary medicines. The company's initial focus is on animal health, where antibiotic resistance is a major issue, contributing to significant food waste and mortality rates.

The funding round, led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, will be used to scale veterinary phage-therapy solutions, advance R&D, and expand the team. This investment recognises the potential of Phagos' approach in combating antimicrobial resistance, which causes millions of deaths annually and could impose substantial global economic costs by 2050.

Phagos' innovative AI-enhanced phage therapies offer a promising solution to the growing problem of antibiotic resistance in animal health. With €25 million in Series A funding, the company is well-positioned to advance its research, scale its solutions, and expand its team, ultimately aiming to reduce bacterial infection-related mortality and food waste.

Read also:

Latest